Allergy Therapeutics PLC Issue of equity in respect of exercise of options (3713K)
September 20 2016 - 11:58AM
UK Regulatory
TIDMAGY
RNS Number : 3713K
Allergy Therapeutics PLC
20 September 2016
20 September 2016
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Issue of equity in respect of the exercise of options
Allergy Therapeutics (AIM:AGY), the fully integrated specialty
pharmaceutical company specialising in allergy vaccines, announces
the issue and allotment of 764,512 new ordinary shares of 0.1p each
in the capital of the Company ("Ordinary Shares") pursuant to the
exercise of 764,512 share options issued under the Company's Long
Term Incentive Programme for executive Management.
Application has been made to the London Stock Exchange for
admission to trading of the new Ordinary Shares on AIM
("Admission"). It is expected that Admission will take place and
that dealings in the new Ordinary Shares on AIM will commence at
8:00 a.m. on 26 September 2016. The new Ordinary Shares will, when
issued, be credited as fully paid and will rank pari passu in all
respects with the existing Ordinary Shares in the capital of the
Company, including the right to receive all dividends or other
distributions made, paid or declared in respect of such shares
after the date of issue of the new Ordinary Shares.
Allergy Therapeutics' enlarged issued ordinary share capital
immediately following Admission will be 589,923,020 Ordinary Shares
with voting rights attached. The Company has no Ordinary Shares in
Treasury; therefore, the total number of voting rights in Allergy
Therapeutics is 589,923,020. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify an interest in,
or a change to their interest in, the share capital of the Company
under the FCA's Disclosure and Transparency Rules.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura
Thornton
allergytherapeutics@consilium-comms.com
Note to editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty
pharmaceutical company focussed on the treatment and diagnosis of
allergic disorders including immunotherapy vaccines that cure
disease. The Company sells proprietary products and third party
products from its subsidiaries in nine major European countries and
via distribution agreements in an additional ten countries.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with MHRA-approved manufacturing
facilities. The Company employs c.420 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEEASNEASSKEFF
(END) Dow Jones Newswires
September 20, 2016 11:58 ET (15:58 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Sep 2023 to Sep 2024